B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NR2F2

MOLECULAR TARGET

nuclear receptor subfamily 2 group F member 2

UniProt: P24468NCBI Gene: 702613 compounds

NR2F2 (nuclear receptor subfamily 2 group F member 2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NR2F2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1cycloheximide1.393
2Anisomycin1.102
3Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.1.102
4Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.1.102
5Digoxin1.102
6dihydrorotenone1.102
7Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,1.102
8Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.1.102
9Tubercidin1.102
10alsterpaullone0.691
11clofilium tosylate0.691
12Dasatinib0.691
13Stavudine0.691

About NR2F2 as a Drug Target

NR2F2 (nuclear receptor subfamily 2 group F member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented NR2F2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NR2F2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.